2 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
Follow Progressive Pulmonary Fibrosis: new trials by email Literature Review of Progressive Pulmonary Fibrosis trials Research Report on Progressive Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) AP01 - Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 340 | 2025-04-17 | 2026-10-02 |
| A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis BI 1839100, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Terminated | Boehringer Ingelheim | 85 | 2024-08-28 | 2026-09-23 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis AP01, Placebo - Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Avalyn Pharma Inc. | 398 | 2024-04-03 | 2026-10-16 |
| Xenon MRI and Progressive ILD Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Duke University | 60 | 2022-07-19 | 2026-06-11 |
Idiopathic Pulmonary Fibrosis (3) · Alveolitis, Extrinsic Allergic (1) · Lung Diseases, Interstitial (1) · Pulmonary Fibrosis (1)
Lung Diseases (4) · Respiratory Tract Diseases (4) · Lung Diseases, Interstitial (3) · Pulmonary Fibrosis (3) · Fibrosis (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Hypersensitivity (1)
Avalyn Pharma Inc. (2) · Boehringer Ingelheim (1) · Duke University (1)
United States (4) · Australia (3) · Canada (3) · France (3) · Germany (3) · Italy (3) · Netherlands (3) · New Zealand (3) · Spain (3) · United Kingdom (3) · Argentina (2) · Belgium (2) · Czechia (2) · Poland (2) · China (1)
2023 (1)